The main results of the phase 3 Reverse-it trial

Reported from ACC.25

Luis Ortega-Paz interviews Deepak L. Bhatt about the results of the Phase 3 Reverse-it trial which he presented during the ACC.25 in Chicago.

According to the study, bentracimab effectively restored platelet function and achieved hemostasis in urgent surgery or major bleeding cases, with a favourable safety profile, making it a promising option for ticagrelor reversal pending regulatory review.